6533b85afe1ef96bd12b969a
RESEARCH PRODUCT
Droloxifene-Induced Spikes of Tumor Markers Predict Benefit of Therapy
R Kreienbergsubject
Cancer Researchmedicine.medical_treatmentRadioimmunoassayAntineoplastic AgentsBreast NeoplasmsBreast cancerPredictive Value of TestsmedicineHumansAntigens Tumor-Associated CarbohydrateAgedTumor markerChemotherapybusiness.industryEstrogen AntagonistsCancerRadioimmunoassayMiddle Agedmedicine.diseaseAntiestrogenTamoxifenTreatment OutcomeOncologyPredictive value of testsCancer researchDrug EvaluationFemalebusinessTamoxifenmedicine.drugdescription
In the clinical monitoring of cancer, tumor marker proteins may reflect the status of the disease. In cases with radio- and chemotherapy, spikes of tumor markers were found shortly after starting the therapy. These spikes were interpreted as a sign of tumor lysis. Recently during therapy of breast cancer with the new antiestrogen droloxifene, spikes of CA 125 and CA 15-3 were also found in about one-third of patients responding to therapy. The peaks of these initial increases were recorded between 14 and 60 days after the onset of treatment, with maximum concentrations up to 1,890% of the initial value. Marker concentrations decreased thereafter, to new baselines at or below the initial values. Objective clinical responses with measurable reduction of tumor mass were observed during the spikes. These results were never observed previously with other antiestrogen treatment and may be interpreted as lysis of tumor cells.
year | journal | country | edition | language |
---|---|---|---|---|
1991-01-01 | American Journal of Clinical Oncology |